CNS Protein Therapeutics ("CNS-PT") is privately-held biotechnology company developing novel growth factors for the treatment of human diseases. Our lead candidate CNS001 represents a new generation of growth factors characterized by its ability to correct protein misfolding. CNS001 is indicated for Parkinson's Disease and Ischemic Heart Disease.